[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578775":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":49,"collaborators":52,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":83,"whyStopped":20,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Università degli Studi di Ferrara","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Salbutamol","EXPERIMENTAL","All patients will received ventilatory support with HFNC by adjusting gas flows to 30 L\u002Fmin with 100% relative humidity, heated to 37 C, adjusting FiO2 levels to maintain SpO2 between 92 and 96%. After 20 min, each patient remaining on ventilatory support with HFNC will receive administration of salbutamol 2.5 mg via the vibrating mesh nebulizer (VMN) (Aerogen Solo®, Aerogen Ltd., Galway, Ireland) positioned immediately downstream of the humidification chamber of the HFNC system, using the dedicated connector.",[13],"Drug: salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)","To evaluate the patient's respiratory effort, the pressure-time product (PTPes) and the delta of Pes oscillations during inspiration (∆ Pes) will be obtained from the analysis of the Pes curve. Global and regional pulmonary tidal volumes will be evaluated with Electrical Impedance Tomography",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Carlo Alberto Volta, Professor","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Savino Spadaro, Associate professor","CONTACT","+39 0532 293111","spdsvn@unife.it",{"name":23,"role":28,"phone":20,"phoneExt":20,"email":32},"vlc@unife.it",[34],{"facility":35,"status":20,"city":36,"state":20,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Azienda ospedaliera Universitaria di Ferrara","Ferrara","44121","Italy","IT",{"type":41,"coordinates":42},"Point",[43,44],11.62057,44.83804,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":20,"phoneExt":20,"email":30},"Savino Spadaro, Associate Professor",{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Savino Spadaro","Professor",[53],{"name":54,"class":55},"Aerogen","INDUSTRY","100578775","phase-2-physiological-effects-of-nebulized-salbutamol-in-acute-respiratory-failure-patients-on-hfnc-100578775",false,"NCT06815679","Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC","The Physiological Effects of Nebulized Salbutamol in Patients With Acute Respiratory Failure During HFNC","PENSAFE-HFNC","Inclusion Criteria:\n\n* • Age \\> 18, \\\u003C 90 years\n\n  * Non-intubated critically ill patients with AHRF due to pneumonia (diagnosis is based on the presence of infiltrates on chest X-ray and the onset of clinical signs of infection less than 7 days earlier)\n  * PaO2\u002FFiO2 ≤ 300 mmHg\n  * Patients receiving oxygen therapy\n\nExclusion Criteria:\n\n* • Age \\\u003C 18 years\n\n  * Hypercapnia (PaCO2 \\> 50 mmHg)\n  * Hemodynamic instability (Systolic blood pressure \\\u003C 90 mmHg or Mean arterial pressure \\\u003C 60 or high dose of vasoactive drugs)\n  * Tachycardia or tachyarrhythmia (HR \\> 130 b\u002Fmin)\n  * Known allergy or intolerance to salbutamol\n  * Patient has received inhaled therapy with short-acting beta 2 agonists \\\u003C 8 hours before or with long-acting beta 2 agonists \\\u003C 24 hours before\n  * Acute exacerbation of COPD or bronchial asthma\n  * Cardiogenic pulmonary edema\n  * GCS ≤ 12\n  * Contraindication for EIT (e.g. ICD)\n  * Pregnancy\n  * Patient refuses to participate","ALL","18 Years","90 Years",{"count":68,"type":69},20,"ESTIMATED","INTERVENTIONAL",[72,73],"PHASE2","PHASE3","This is a prospective physiological interventional study that assess the feasibility and safety of administering salbutamol using a vibrating mesh nebulizer during HFNC in patients with acute hypoxemic respiratory failure (AHRF). We evaluate whether this method of salbutamol delivery can reduce inspiratory effort and improve global and regional lung ventilation in AHRF patients. To achieve this, the study will record and analyze the following: esophageal pressure (Pes) curves, global and regional tidal volumes, minute ventilation, and changes in global and regional lung ventilation assessed through Electrical Impedance Tomography (EIT).",[76,77],"Acute Respiratory Failure","Pneumonia",[79,80,81,82],"salbutamol","acute respiratory failure","high flow nasal cannalae","aerosol delivery","NOT_YET_RECRUITING","2025-02-03",{"date":86,"type":87},"2025-02-07","ACTUAL",{"date":89,"type":69},"2025-03-01",{"date":91,"type":69},"2026-07",{"name":5,"class":6},1]